Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors

PURPOSE: Although EGF receptor tyrosine kinase inhibitors (EGFR-TKI) have shown dramatic effects against EGFR mutant lung cancer, patients ultimately develop resistance by multiple mechanisms. We therefore assessed the ability of combined treatment with the Met inhibitor crizotinib and new generatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Nanjo, Shigeki, Yamada, Tadaaki, Nishihara, Hiroshi, Takeuchi, Shinji, Sano, Takako, Nakagawa, Takayuki, Ishikawa, Daisuke, Zhao, Lu, Ebi, Hiromichi, Yasumoto, Kazuo, Matsumoto, Kunio, Yano, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873434/
https://www.ncbi.nlm.nih.gov/pubmed/24386407
http://dx.doi.org/10.1371/journal.pone.0084700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873434/
https://www.ncbi.nlm.nih.gov/pubmed/24386407
http://dx.doi.org/10.1371/journal.pone.0084700

Ejemplares similares